---
layout: post
title: "港股、A股通生物制药板块逆势走强！周末利好频传 新冠药概念迎“强心针”！(附股)"
date: 2022-02-21 14:50:20 +0800
categories: emnews
tags: 东财滚动新闻
---
> 周一港A两地生物制药板块走强，截至发稿，港股方面，开拓药业-B涨超8%，君实生物涨超6%，凯莱英涨超3%，康希诺生物-B涨超2%；A股通方面，新华制药涨近10%，健康元涨近9%，君实生物-U涨超6%，康希诺-U涨近2%。

<p>周一港A两地生物制药板块走强，截至发稿，港股方面，<span id="Info.116.09939"><a href="http://quote.eastmoney.com/unify/r/116.09939" class="keytip" data-code="116,09939">开拓药业-B</a></span>涨超8%，<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>涨超6%，<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>涨超3%，<span id="Info.116.06185"><a href="http://quote.eastmoney.com/unify/r/116.06185" class="keytip" data-code="116,06185">康希诺生物-B</a></span>涨超2%；A股通方面，<span id="stock_0.000756"><a href="http://quote.eastmoney.com/unify/r/0.000756" class="keytip" data-code="0,000756">新华制药</a></span><span id="quote_0.000756"></span>涨近10%，<span id="stock_1.600380"><a href="http://quote.eastmoney.com/unify/r/1.600380" class="keytip" data-code="1,600380">健康元</a></span><span id="quote_1.600380"></span>涨近9%，<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>-U涨超6%，<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺-U</a></span><span id="quote_1.688185"></span>涨近2%。<a href="https://hk.eastmoney.com/a/202202162277791536.html">(海外投资者如何投资A股通？)</a><br /></p><p>在刚刚过去的周末，新冠产业链利好频传。</p><p>2月20日晚，<strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span><span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>，公司再签大订单，<span id="Info.3300"><a href="http://data.eastmoney.com/zdht/" class="infokey">合同</a></span>金额达35.42亿元。</strong></p><p>此外，在上周六，<strong>我国批准新冠疫苗“混打”加强针，可选智飞或康希诺疫苗。</strong></p><p>2月19日，国家卫生健康委疾控局副局长吴良有透露，根据新冠病毒疫苗研发使用进展情况，近日，经国务院联防联控机制批准，国家卫生健康委已经开始部署序贯加强免疫接种。</p><p>此外，据华尔街日报报道，<strong>美国正在考虑开展第四针新冠疫苗(即第二针加强针)接种。</strong></p><p>新冠疫苗加强针政策公布后，<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>纷纷发布<span id="Info.315"><a href="http://data.eastmoney.com/report/hyyb.html" class="infokey">行业研报</a></span>进行投资机会分析。</p><p><span id="stock_1.601162"><a href="http://quote.eastmoney.com/unify/r/1.601162" class="keytip" data-code="1,601162">天风证券</a></span><span id="quote_1.601162"></span>指出，中国加强免疫接种为免费接种，潜在需求约7.29亿人。</p><p>截至2022年2月15日中国累计接种新冠疫苗约30.57亿剂次，疫苗接种总人数为12.67亿，其中完成全程接种12.31亿人，已完成第三针加强免疫接种人数约5.02亿，未来第三针加强新冠疫苗接种需求约7.29亿人，占完成基础免疫的59%。</p><p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.601162" class="em_stock_key_common" data-code="1,601162">天风证券</span>称，新冠疫苗序贯接种获批，中国将加快加强针接种，新冠疫苗继续贡献<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>，</strong>建议关注加强针相关标的：<strong><span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、康希诺</strong>和<strong><span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>。</strong></p><p><span id="stock_1.601878"><a href="http://quote.eastmoney.com/unify/r/1.601878" class="keytip" data-code="1,601878">浙商证券</a></span><span id="quote_1.601878"></span>认为，国内疫苗公司的新冠疫苗研发、销售是综合能力的体现，<span web="1" href="http://quote.eastmoney.com/unify/r/1.601878" class="em_stock_key_common" data-code="1,601878">浙商证券</span>更建议从技术平台搭建、国际化能力拓展、国内商业化能力提升等角度看待国内疫苗公司在新冠疫苗机会背后的能力跃迁。</p><p>从对上市公司影响的角度，<strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.601878" class="em_stock_key_common" data-code="1,601878">浙商证券</span>建议关注康希诺、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300601" class="em_stock_key_common" data-code="0,300601">康泰生物</span>等公司加强针推广接种情况。</strong></p><p><strong>开源<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>发<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>指，新冠疫苗加强针“序贯接种”即将来临，群体免疫力有望进一步增强。</strong></p><p>开源<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>在研报中给出推荐及受益标的，其中，推荐标的：<strong><span id="stock_1.600285"><a href="http://quote.eastmoney.com/unify/r/1.600285" class="keytip" data-code="1,600285">羚锐制药</a></span><span id="quote_1.600285"></span>、<span id="stock_0.002044"><a href="http://quote.eastmoney.com/unify/r/0.002044" class="keytip" data-code="0,002044">美年健康</a></span><span id="quote_0.002044"></span>、<span id="Info.116.06078"><a href="http://quote.eastmoney.com/unify/r/116.06078" class="keytip" data-code="116,06078">海吉亚医疗</a></span>、<span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>、<span id="stock_0.300143"><a href="http://quote.eastmoney.com/unify/r/0.300143" class="keytip" data-code="0,300143">盈康生命</a></span><span id="quote_0.300143"></span>、<span id="stock_0.002390"><a href="http://quote.eastmoney.com/unify/r/0.002390" class="keytip" data-code="0,002390">信邦制药</a></span><span id="quote_0.002390"></span></strong>等。</p><p>受益标的：<strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>(AH股)、<span id="Info.116.02096"><a href="http://quote.eastmoney.com/unify/r/116.02096" class="keytip" data-code="116,02096">先声药业</a></span>(H股)、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06185" class="em_stock_key_common" data-code="116,06185">康希诺生物-B</span>(H股)、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06821" class="em_stock_key_common" data-code="116,06821">凯莱英</span>(AH股)、<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>、<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>(H股)、<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>、<span id="Info.116.02273"><a href="http://quote.eastmoney.com/unify/r/116.02273" class="keytip" data-code="116,02273">固生堂</a></span>(H股)、<span id="Info.116.00874"><a href="http://quote.eastmoney.com/unify/r/116.00874" class="keytip" data-code="116,00874">白云山</a></span>(AH股)、<span id="stock_0.000538"><a href="http://quote.eastmoney.com/unify/r/0.000538" class="keytip" data-code="0,000538">云南白药</a></span><span id="quote_0.000538"></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>、<span id="stock_1.601567"><a href="http://quote.eastmoney.com/unify/r/1.601567" class="keytip" data-code="1,601567">三星医疗</a></span><span id="quote_1.601567"></span>等</strong>。</p><p>以下为港股以及A股通生物制药板块相关标的：</p><center><img src="https://dfscdn.dfcfw.com/download/D25311012315895721019_w878h1760.jpg" width="580" emheight="1163" orginial_src="https://dfscdn.dfcfw.com/download/D25311012315895721019_w878h1760_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><center><img src="https://dfscdn.dfcfw.com/download/D25283489772272445634_w878h1760.jpg" width="580" emheight="1163" orginial_src="https://dfscdn.dfcfw.com/download/D25283489772272445634_w878h1760_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>相关阅读：</strong></p><p><strong><a href="https://finance.eastmoney.com/a/202202212282400044.html">疫苗股卷土重来？中国启动“混打”加强针 美国筹划第四针 券商最新解读</a><br /></strong></p><p><strong><a href="https://finance.eastmoney.com/a/202202212282394183.html">医药行业一周观察：序贯接种落地 关注新冠疫苗加强针和出海机会</a><br /></strong></p><p><strong><a href="https://finance.eastmoney.com/a/202202212282365633.html">周末重磅！800亿巨头再签大单 新冠产业链频传利好 医药股开盘见</a><br /></strong></p><p class="em_media">（文章来源：哈富<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>）</p>

<http://hk.eastmoney.com/news/11382,202202212283137946.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)